Zuzana KLEPCOVÁ, Katarína KALINOVÁ, Dominika VESELÍNYOVÁ, Miroslava RABAJDOVÁ

Ústav lekárskej a klinickej biochémie, UPJŠ v Košiciach, Lekárska fakulta, prednostka prof. Ing. M. Mareková, CSc.

SUMMARY
Triple-negative breast cancer is the most agressive and prevalent subtype of breast cancer in women worldwide. Currently, chemotherapy remains main modality for the treatment at an early stage, as there is no approved targeted therapy for early triple negative breast cancer. MicroRNA plays a key role in the post-transcriptional regulation of genes involved in the key biological processes, namely proliferation, differentiation, angiogenesis, migration, programm cell death, and carcinogenesis. In triple negative nerast cancer cells, microRNA make major contributions to the diagnosis, prognosis, and treatment. Thus it is suggested that microRNA-based therapeutics could be a promising approach in the treatment of triple negative breast cancer. The present article provides a characterization of the biogenesis of miRNA molecules, discusses about microRNAs as prognostic and diagnostic tools of TNBC. It also provides information about treatment applications of miRNAs as antiproliferative and antimetatstatic agents in TNBC.

Key words: microRNA, triple negative breast cancer, biomarker.

Lek Obz, 2020, 69 (4): 134 – 139